[Artículo traducido] Acetato de abiraterona en dosis reducida para el tratamiento del cáncer de próstata: estudio de cohorte observacional
This study provides evidence supporting the use of low-dose abiraterone in patients with metastatic prostate cancer, showing survival and progression outcomes comparable to those of the standard-dose. This approach may improve access to treatment; however, larger studies are needed to validate these findings.
Authors
- María Lourdes Posadas‐Martínez (ORCID: https://orcid.org/0000-0003-1403-7069)
- Mariana Andrea Burgos (ORCID: https://orcid.org/0000-0001-6161-9147)
- Federico Cayol
- Sergio Terrasa (ORCID: https://orcid.org/0000-0002-5246-0709)
- Gabriela Buela (ORCID: https://orcid.org/0009-0007-1039-1032)
- L. Basbus
- M. Aymar
- Luis Angel Di-Giuseppe
- Rodney Alexander Ramirez-Murillo
- Milagros Cornec
Institutions
- Hospital Italiano de Buenos Aires (AR)
- Universidad Hospital Italiano (AR)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.farma.2025.10.010
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00